Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027

2.1 Global ALS Market Expected to Experience Explosive Growth by 2027
2.2 Pharmaceutical Companies Target Novel MOAs in a Market with Few Approved Therapies
2.3 Several Key Unmet Needs Identified in the ALS Market, Providing Opportunity for New Players
2.4 Several Different Classes in the ALS Pipeline Look to Fill the Gaps in the Market
2.5 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Symptoms
4.3.1 Complications
4.4 Quality of Life

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for ALS (2017-2027)
5.5.1 Diagnosed Prevalent Cases of ALS
5.5.2 Age-Specific Diagnosed Prevalent Cases of ALS
5.5.3 Sex-Specific Diagnosed Prevalent Cases of ALS
5.5.4 Diagnosed Prevalent Cases of ALS by Type
5.5.5 Total Prevalent Cases of ALS
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6.1 Overview

7.1 Overview
7.2 Faster Diagnosis
7.3 Curative Agent
7.4 Extended Patient Survival
7.5 Identification of Biomarkers Associated with ALS

8.1 Overview
8.1.1 Novel Targets
8.1.2 Disease-Modifying Therapies
8.1.3 Reformulations
8.2 Clinical Trials Design
8.2.1 Endpoints
8.2.2 Length of Clinical Trials
8.2.3 Patient Recruitment

9.1 Overview
9.2 Innovative Early-Stage Approaches

10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan

11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Patients
11.3.3 Percent Drug-Treated Patients
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch and Patent Expiry Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Generic Erosion
11.3.9 Pricing of Pipeline Agents
11.4 Primary Research - KOLs Interviewed for This Report
11.4.1 KOLs
11.4.2 Payers
11.5 Primary Research - Prescriber Survey
11.6 About the Authors
11.6.1 Analyst
11.6.2 Therapy Area Director
11.6.3 Epidemiologist
11.6.4 Managing Epidemiologist
11.6.5 Global Director of Therapy Analysis and Epidemiology
11.6.6 Global Head and EVP of Healthcare Operations and Strategy
11.7 About
11.8 Contact
11.9 Disclaimer

Table 1: ALS: Key Metrics in the 7MM
Table 2: Gene Involved in the Familial Forms of ALS
Table 3: Symptoms of ALS
Table 4: Risk Factors and Comorbidities for ALS
Table 5: Leading Treatments for ALS, 2018
Table 6: Treatment Guidelines for ALS
Table 7: Comparison of Therapeutic Classes in Development for ALS, 2017-2027
Table 8: Innovative Early-Stage Approaches for ALS, 2018
Table 9: Clinical Benchmark of Key Pipeline Drugs - ALS
Table 10: Commercial Benchmark of Key Pipeline Drugs - ALS
Table 11: Key Events Impacting Sales for ALS, 2017-2027
Table 12: ALS Market - Global Drivers and Barriers, 2017-2027
Table 13: Key Historical and Projected Launch Dates for ALS
Table 14: Key Historical and Projected Patent Expiry Dates for ALS
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for ALS in 2017 and 2027
Figure 2: Competitive Assessment of Marketed and Pipeline Drugs, Benchmarked Against the SOC, Rilutek
Figure 3: Overview of the human body and muscles involved in ALS
Figure 4: Pathophysiology of ALS
Figure 5: Staging Systems for ALS
Figure 6: 7MM, Age-Standardized Diagnosed Prevalence of ALS, Ages =40 Years, 2017
Figure 7:Sources Used for Diagnosed Prevalent Cases of ALS
Figure 8:Sources Used for Diagnosed Prevalent Cases of ALS Type
Figure 9: 7MM, Diagnosed Prevalent Cases of ALS, Men and Women, Ages =40 Years, 2017
Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of ALS, Men and Women, 2017
Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of ALS, Men and Women, Ages =40 Years, 2017
Figure 12: 7MM, Diagnosed Prevalent Cases of ALS by Type, Men and Women, Ages =40 Years, 2017
Figure 13: 7MM, Total Prevalent Cases of ALS, Men and Women, Ages =40 Years, 2017
Figure 14: Unmet Needs and Opportunities in ALS
Figure 15: Overview of the Development Pipeline in ALS
Figure 16: Key Phase II and III Trials for Promising Pipeline Agents
Figure 17:Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC), Rilutek
Figure 18: Global (7MM) Sales Forecast by Country for ALS in 2017 and 2027